跳至主要内容
临床试验/NCT02497521
NCT02497521招募中不适用

The German ADPKD Tolvaptan Treatment Registry is a Prospective, Observational, Multicentric Study of Patients Suffering From ADPKD That Are Considered for Tolvaptan Treatment.

University of Cologne12 个研究点 分布在 1 个国家目标入组 2,000 人开始时间: 2015年11月最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
2,000
试验地点
12
主要终点
Drug dosing and titration as a measure of changes in real-life setting

研究概览

简要总结

The German ADPKD Tolvaptan Treatment Registry is a prospective, observational, multicentric study of patients suffering from ADPKD that are considered for tolvaptan treatment. All ADPKD patients that are evaluated for treatment indication, or that are planned to be treated with tolvaptan, or that are already treated with tolvaptan are eligible. This registry is designed to provide "real-world" data on treatment management of patients with ADPKD.

详细描述

A substantial number of ADPKD patients treated in our center or referred to our center for counseling are considered eligible for tolvaptan treatment and, thus, will be invited to enter the registry. Furthermore, many patients with ADPKD are treated by nephrologists in practices. We operate a network with many of these practices and will expand this network. Patients can be enrolled - after having obtained approval by the local ethics committee - at external sites (expected number: about 500 patients per year). We are also closely liaised with the German self-help group PKDCure (PKD Familiaere Zystennieren e.V.), which is dedicated to ADPKD-linked research. Recruitment of patients will be facilitated by intensified interacting with these groups. Usually, patients that are referred to our institution for evaluation or counseling are regularly seen once a year. No additional trial-related visits in our institution will be required which is in line with the observational nature of the trial. However, data recording is not restricted to parameters assessed at our center but does include also parameters assessed by the treating physician.

SOPs (Standard Operating Procedures) that include further diagnostic tests like MRI are applied routinely in ADPKD patient management in our institution. The data obtained from these tests will be entered in the registry.

At enrolment, clinical, laboratory data and imaging study findings are collected after obtaining informed consent. The parameters listed below constitute the core data set, additional parameters can be included if considered essential.

Clinical data:

  • demographic data (sex, age, height, weight)
  • family history
  • genotype (if available)
  • extrarenal ADPKD manifestations
  • co-morbidities
  • medication
  • physical examination
  • blood pressure
  • no. of extrarenal and renal complications in the past 12 months (urinary tract infections, pain episodes, macrohematuria, kidney stones, hospital admissions, ...)

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age > 18 years
  • ADPKD proven by positive family history and evidence of renal cysts or diagnosed by treating physician
  • Presentation at our center for tolvaptan treatment indication, or tolvaptan treatment planned, or tolvaptan already started

排除标准

  • Patients not capable of giving informed consent
  • End stage renal disease requiring renal replacement therapy
  • Patients receiving tolvaptan as "off-label use"

结局指标

主要结局

Drug dosing and titration as a measure of changes in real-life setting

时间窗: 10 years

Drug dosing and titration as a measure of maximum dose and the final dose and how fast it is achieved

Urine osmolarity as a measure of appropriate dosing

时间窗: 10 years

Data on urine osmolarity will be collected to measure appropriate dosing to provide the desired protective effect

Evaluation of rate of drug discontinuation and average Duration of therapy

时间窗: 10 years

Evaluation of rate of drug discontinuation and average Duration of therapy

次要结局

  • Liver enzymes(10 years)
  • Clinical and biochemical characteristics during follow-up(10 years)
  • Clinical and biochemical characteristics at enrolment and treatment initiation(10 years)
  • Evolution of TKV(10 years)
  • Demographics(10 years)
  • Side effects(10 years)
  • Evolution of estimated glomerular Filtration rate (eGFR) over the Observation period(10 years)
  • Urinary output(10 years)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Roman Müller

MD, Prof.

University Hospital of Cologne

研究点 (12)

Loading locations...

相似试验